Collegium Pharmaceutical, Inc.
Símbolo: COLL
NASDAQ
37.51
USDPrecio de mercado actual
25.1608
Ratio PER
1.5484
Ratio PEG
1.20B
Capitalización MRK
- 0.00%
Rendimiento DIV
Collegium Pharmaceutical, Inc. (COLL) Estados Financieros
Balance de situación
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1210.06 | 310.5 | 173.7 | 186.4 | |||||||||||
balance-sheet.row.short-term-investments | 159.35 | 71.6 | 0 | 0 | |||||||||||
balance-sheet.row.net-receivables | 707.98 | 179.5 | 183.1 | 105.8 | |||||||||||
balance-sheet.row.inventory | 125.38 | 32.3 | 46.5 | 17.4 | |||||||||||
balance-sheet.row.other-current-assets | 51.76 | 0.1 | 16.7 | 0 | |||||||||||
balance-sheet.row.total-current-assets | 2110.28 | 537.6 | 420 | 315.5 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 94.93 | 22 | 26.4 | 27.1 | |||||||||||
balance-sheet.row.goodwill | 535.43 | 133.9 | 133.7 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 1900.47 | 421.7 | 567.5 | 268.7 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 2435.9 | 555.6 | 701.2 | 268.7 | |||||||||||
balance-sheet.row.long-term-investments | 3.52 | 1 | 2.5 | 2.5 | |||||||||||
balance-sheet.row.tax-assets | 100.57 | 26.3 | 23.9 | 78 | |||||||||||
balance-sheet.row.other-non-current-assets | 3.89 | 0.8 | 0.1 | 0.1 | |||||||||||
balance-sheet.row.total-non-current-assets | 2638.81 | 605.7 | 754.1 | 376.5 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 4749.1 | 1143.3 | 1174.1 | 692.1 | |||||||||||
balance-sheet.row.account-payables | 17.76 | 8.7 | 39.6 | 33.4 | |||||||||||
balance-sheet.row.short-term-debt | 737.3 | 184.3 | 163.6 | 49.2 | |||||||||||
balance-sheet.row.tax-payables | 21.59 | 7.1 | 4.4 | 3.2 | |||||||||||
balance-sheet.row.long-term-debt-total | 2223.97 | 490 | 709.2 | 258.8 | |||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 1015.23 | 264.9 | 66.9 | 147.8 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 2223.97 | 490 | 709.2 | 258.8 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 29.98 | 7.1 | 8.2 | 8.8 | |||||||||||
balance-sheet.row.total-liab | 3994.26 | 947.9 | 979.3 | 489.1 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0.15 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.retained-earnings | -1082.85 | -233.2 | -281.3 | -256.3 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.08 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 1837.62 | 428.6 | 476.1 | 459.2 | |||||||||||
balance-sheet.row.total-stockholders-equity | 754.84 | 195.4 | 194.8 | 202.9 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 4749.1 | 1143.3 | 1174.1 | 692.1 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 754.84 | 195.4 | 194.8 | 202.9 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 4749.1 | - | - | - | |||||||||||
Total Investments | 161.9 | 71.6 | 2.5 | 2.5 | |||||||||||
balance-sheet.row.total-debt | 2961.26 | 674.3 | 872.8 | 258.8 | |||||||||||
balance-sheet.row.net-debt | 1910.56 | 435.3 | 699.1 | 72.3 |
Estado de tesorería
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 48.16 | 48.2 | -25 | 71.5 | |||||||||||
cash-flows.row.depreciation-and-amortization | 149.26 | 149.3 | 138.9 | 68.9 | |||||||||||
cash-flows.row.deferred-income-tax | -2.15 | -2.2 | -8.4 | -78 | |||||||||||
cash-flows.row.stock-based-compensation | 27.14 | 27.1 | 22.9 | 24.3 | |||||||||||
cash-flows.row.change-in-working-capital | 21.73 | 21.7 | -12.7 | 13.5 | |||||||||||
cash-flows.row.account-receivables | 3.59 | 3.6 | -21.8 | -22.5 | |||||||||||
cash-flows.row.inventory | 14.17 | 14.2 | 48.3 | -2.3 | |||||||||||
cash-flows.row.account-payables | 5.06 | 5.1 | -0.7 | -5.8 | |||||||||||
cash-flows.row.other-working-capital | 23.77 | -1.1 | -38.5 | 44.1 | |||||||||||
cash-flows.row.other-non-cash-items | 30.62 | 30.6 | 8.5 | 3.4 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 274.75 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.46 | -0.5 | -1.6 | -1.9 | |||||||||||
cash-flows.row.acquisitions-net | -41.66 | 0 | -572.1 | 0 | |||||||||||
cash-flows.row.purchases-of-investments | -92.35 | -92.4 | 0 | 0 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 22 | 22 | 0 | 0 | |||||||||||
cash-flows.row.other-investing-activites | 41.66 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -70.81 | -70.8 | -573.7 | -1.9 | |||||||||||
cash-flows.row.debt-repayment | -301.14 | -301.1 | -75 | -50 | |||||||||||
cash-flows.row.common-stock-issued | 1.84 | 9.1 | 11.8 | 12.7 | |||||||||||
cash-flows.row.common-stock-repurchased | -75.05 | -75 | -14.1 | -47.9 | |||||||||||
cash-flows.row.dividends-paid | -57.53 | -9.1 | 0 | -12.7 | |||||||||||
cash-flows.row.other-financing-activites | 291.69 | 236 | 514 | 8.6 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -140.18 | -140.2 | 436.7 | -89.3 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | 63.76 | 63.8 | -12.7 | 12.3 | |||||||||||
cash-flows.row.cash-at-end-of-period | 1056.4 | 240 | 176.2 | 189 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 992.64 | 176.2 | 189 | 176.7 | |||||||||||
cash-flows.row.operating-cash-flow | 274.75 | 274.7 | 124.2 | 103.6 | |||||||||||
cash-flows.row.capital-expenditure | -0.46 | -0.5 | -1.6 | -1.9 | |||||||||||
cash-flows.row.free-cash-flow | 274.29 | 274.3 | 122.6 | 101.6 |
Fila de la Cuenta de Resultados
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 566.77 | 566.8 | 463.9 | 276.9 | |||||||||||
income-statement-row.row.cost-of-revenue | 240.6 | 240.6 | 254.4 | 126.3 | |||||||||||
income-statement-row.row.gross-profit | 326.17 | 326.2 | 209.5 | 150.6 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.operating-expenses | 159.21 | 159.2 | 176.2 | 128.4 | |||||||||||
income-statement-row.row.cost-and-expenses | 399.81 | 399.8 | 430.6 | 254.7 | |||||||||||
income-statement-row.row.interest-income | 15.62 | 15.6 | 1 | 0 | |||||||||||
income-statement-row.row.interest-expense | 83.34 | 83.3 | 63.2 | 21 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -91.23 | -23.5 | 75.7 | 43.3 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.total-operating-expenses | -91.23 | -23.5 | 75.7 | 43.3 | |||||||||||
income-statement-row.row.interest-expense | 83.34 | 83.3 | 63.2 | 21 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 152 | 149.3 | 138.9 | 68.9 | |||||||||||
income-statement-row.row.ebitda-caps | 331.83 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 166.96 | 167 | -104.6 | -46.7 | |||||||||||
income-statement-row.row.income-before-tax | 75.73 | 75.7 | -28.8 | -3.4 | |||||||||||
income-statement-row.row.income-tax-expense | 27.58 | 27.6 | -3.8 | -74.9 | |||||||||||
income-statement-row.row.net-income | 48.16 | 48.2 | -25 | 71.5 |
Preguntas frecuentes
Cuánto es Collegium Pharmaceutical, Inc. (COLL) activos totales?
Collegium Pharmaceutical, Inc. (COLL) los activos totales son 1143308000.000.
¿Cuáles son los ingresos anuales de la empresa?
Los ingresos anuales son 286454000.000.
¿Cuál es el margen de beneficios de la empresa?
El margen de beneficios de la empresa es 0.575.
¿Qué es el flujo de caja libre de la empresa?
El flujo de caja libre es 8.492.
¿Cuál es el margen de beneficio neto de la empresa?
El margen de beneficio neto es 0.085.
¿Cuáles son los ingresos totales de la empresa?
Los ingresos totales son 0.295.
¿Qué es Collegium Pharmaceutical, Inc. (COLL) beneficio neto (ingresos netos)?
El beneficio neto (ingresos netos) es 48155000.000.
¿Cuál es la deuda total de la empresa?
La deuda total es 674283000.000.
¿Cuál es la cifra de gastos de explotación?
Los gastos de explotación son 159208000.000.
¿Cuál es la cifra de tesorería de la empresa?
La tesorería de la empresa es 238947000.000.